Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation

ABSTRACT: Data supporting the manuscript: A methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation

INSTRUMENT(S): timsTOF fleX

ORGANISM(S): Mus Musculus (ncbitaxon:10090)

SUBMITTER: Jarrod A Marto

PROVIDER: MSV000096296 | MassIVE | Tue Nov 05 08:28:00 GMT 2024

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

METTL1-mediated m7G tRNA modification drives oncogenic transformation

Project description:METTL1-mediated m7G tRNA modification drives oncogenic transformation

| PRJNA631030 | ENA

ADAT2/3 complex-deposited tRNA inosines drives oncogenic transformation

Project description:ADAT2/3 complex-deposited tRNA inosines drives oncogenic transformation

| PRJNA980179 | ENA

Epigenetic enhancer changes during oncogenic transformation

Project description:Epigenetic enhancer changes during oncogenic transformation

| PRJNA393898 | ENA

ADAT2/3 complex-deposited tRNA inosines drives oncogenic transformation

Project description:Transfer RNAs (tRNAs) are subject to numerous posttranscriptional modifications that influence their maturation, stability, and function. Adenosine to Inosine (A-to-I) editingin thetRNA anticodon stem loop is an important modification that influences anticodon-codon recognition.However,the implications of tRNA editing in cancer and its potential for diagnostic and therapeutic applicationsare not yet well understood.We showed that the ADAT2/3 enzyme complex, responsible for this modification in humans, is amplified and overexpressed in several tumor types,with a higher amplification rate in sarcoma tumors, particularly liposarcomas. We determine that the ADAT complex works as an oncogene in these tumors and that its inhibition reduces tumor growth, offering a new approach to cancer treatment. In addition, we provided insight into the mechanisms of cancer development and progression, demonstrating that tRNA editing is required for higher mRNA translation of oncogenic proteins enriched with specific ADAT-sensitive codons. Thus, ADAT-mediated tRNA modification drives oncogenic transformation by remodeling the set of mRNAs being actively translated to increase expression of proteins that promote proliferation. Our results explain how cancer cells benefit from increased tRNA A-to-I editing and propose ADATs as potential therapeutic targets for the treatment of cancer.

2024-06-04 | GSE234132 | GEO

Kim et al. STRIPAK directs PP2A activity towards MAP4K4 to promote oncogenic transformation

Project description:STRIPAK directs PP2A activity towards MAP4K4 to promote oncogenic transformation

2019-10-04 | MSV000084422 | MassIVE

Epigenetic enhancer changes during oncogenic transformation [ChIP-seq]

Project description:Identification of differential enhancers active during oncogenic transformation, using FAIRE-seq and ChIP-seq for H3K4me1 and H3K27ac

2020-07-11 | GSE101170 | GEO

STRIPAK directs PP2A activity to promote oncogenic transformation

Project description:STRIPAK directs PP2A activity to promote oncogenic transformation

| PRJNA485011 | ENA

Epigenetic enhancer changes during oncogenic transformation [RNA-seq]

Project description:Identification of differential enhancers active during oncogenic transformation, using RNA-seq with FAIRE-seq and ChIP-seq for H3K4me1 and H3K27ac.

2020-07-11 | GSE101241 | GEO

CBFA2T3-GLIS2 oncogenic fusion is sufficient for leukemic transformation

Project description:CBFA2T3-GLIS2 oncogenic fusion is sufficient for leukemic transformation

| PRJNA753108 | ENA

Lineage-specific intolerance to oncogenic drivers restricts histological transformation

Project description:Lineage-specific intolerance to oncogenic drivers restricts histological transformation

| PRJNA1042808 | ENA